瑞典侵袭性脑膜炎球菌分离株的基因组预测疫苗覆盖:Bexsero与Trumenba联合分析
该研究基于瑞典2014—2018年全部侵袭性脑膜炎球菌分离株(n=242),利用PubMLST疫苗覆盖方案评估Bexsero与Trumenba的基因组预测覆盖。总体覆盖分别为55%和57%(p=0.714);两疫苗联合的潜在基因组覆盖达95%,提示可能存在叠加效应,但需表型抗原表达分析确认。
要点
- 瑞典侵袭性脑膜炎球菌总体基因组预测覆盖:Bexsero 55%、Trumenba 57%。
- MenB覆盖Trumenba 90%高于Bexsero 67%(p<0.05)。
- 两疫苗联合的潜在基因组覆盖为95%,需表型验证。
核心结论
- 两疫苗联合对瑞典侵袭性脑膜炎球菌分离株的基因组预测覆盖达95%,提示可能叠加效应,但需表型抗原表达分析确认。
研究设计与样本
- 研究纳入瑞典2014—2018年全部侵袭性脑膜炎球菌分离株(n=242),采用PubMLST数据库的疫苗覆盖方案进行基因组分析。
主要发现
- 总体基因组预测覆盖Bexsero为55%、Trumenba为57%(p=0.714)。
- 血清群特异性覆盖Bexsero与Trumenba分别为:MenB 67%与90%(p<0.05),MenW 93%与4%(p<0.05),MenC 87%与30%(p<0.05),MenY 1%与96%(p<0.05)。
关键数值与推荐
- Bexsero总体覆盖55%,Trumenba总体覆盖57%(p=0.714)。
- MenB覆盖Bexsero 67%、Trumenba 90%(p<0.05);MenW 93%与4%;MenC 87%与30%;MenY 1%与96%(均p<0.05)。
- 两疫苗联合的潜在基因组预测覆盖为95%。
临床怎么用
- 基因组预测覆盖结果可辅助评估Bexsero与Trumenba联合用于MenB相关侵袭性疾病防护的潜在价值。
- 血清群特异性覆盖差异提示联合使用可能扩大覆盖范围,但实际应用前需表型抗原表达分析确认。
局限性
- 联合覆盖为基因组预测结果,需通过表型抗原表达分析进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Two protein-based vaccines (Bexsero® and Trumenba®) are licensed for invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MenB). The aim of this study was to evaluate the possible protection of these vaccines, based on the genomic profiles of IMD isolates. All invasive meningococcal isolates in Sweden during 2014-2018 (n = 242) were analyzed with the vaccine coverage scheme available at the PubMLST database. The overall estimated genomic strain coverage among the Swedish invasive meningococcal isolates was 55% for Bexsero and 57% for Trumenba (p = 0.714). The estimated serogroup-specific coverage for Bexsero respectively Trumenba was: MenB; 67% and 90% (p < 0.05), MenW; 93% and 4% (p < 0.05), MenC; 87% and 30% (p < 0.05) and MenY; 1% and 96% (p < 0.05). With the combination of the two vaccines, the potential genomic-based strain coverage was 95%, indicating a possible additive effect of combining Bexsero and Trumenba, which, however, needs to be confirmed by analysis of phenotypic antigen expression.
引用
- Säll O, Olofsson E, Jacobsson S, et al. High genomic-based predicted strain coverage among invasive meningococcal isolates when combining Bexsero and Trumenba vaccines. Vaccine. 2020. PMID: 32414653. doi:10.1016/j.vaccine.2020.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。